Form 4: SOPHiA GENETICS CTO Receives Equity Awards

SOPHiA GENETICS SA reports that Chief Technology Officer Abhimanyu Verma was granted restricted stock units and stock options on April 2, 2026.

Summary

• Abhimanyu Verma, Chief Technology Officer at SOPHiA GENETICS SA, received a grant of 82,136 restricted stock units (RSUs) and was granted 119,760 share options.
• The RSUs are part of the Issuer's 2021 Equity Incentive Plan and vest over time, with 25% vesting on April 2, 2027, and the remainder vesting quarterly through April 2, 2030.
• The share options also vest over time, with 25% becoming exercisable on April 2, 2027, and the remaining vesting monthly through April 2, 2030.
• The transaction date for these awards was April 2, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports standard executive compensation practices but provides no operational or financial performance data.

Positives

• Grant of equity awards (RSUs and stock options) to a key executive, indicating potential alignment of management interests with shareholder value.
• Long vesting periods for both RSUs and stock options (through April 2030) suggest a focus on long-term retention and company performance.

Negatives

• No financial performance metrics or operational updates are provided in this filing, making it difficult to assess the company's current health.
• The filing solely details equity grants and does not offer insights into revenue, profitability, or strategic progress.

Risks

• Vesting of equity awards is contingent on continued service, meaning a departure of the CTO before vesting would result in forfeiture of these awards.
• The value of these equity awards is subject to the future stock price performance of SOPHiA GENETICS SA.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's financial performance or strategic direction. It solely details equity awards granted to an executive.

Industry Context

StockSavvy.ai notes that the granting of equity awards, such as RSUs and stock options, is a common practice in the technology and biotechnology sectors to attract, retain, and incentivize key personnel, particularly in growth-oriented companies like SOPHiA GENETICS SA.

Stakeholder Impact

• Shareholders: The equity grants align executive incentives with long-term company performance, which could positively impact shareholder value if the company succeeds.
• Employees: The granting of equity to a key executive may signal the company's commitment to its talent pool and growth strategy.
• Management: The CTO receives potential future compensation tied to company performance and continued employment.

Next Steps

• Continued service by Abhimanyu Verma through the vesting dates to receive the full equity awards.
• Monitoring of SOPHiA GENETICS SA's future financial and operational performance to assess the value of these equity awards.

Key Dates

Keywords

SOPHiA GENETICS SA, Form 4, Abhimanyu Verma, Chief Technology Officer, RSU, Stock Options, Equity Grant, Vesting Schedule, Insider Transaction